Key Insights

Highlights

Success Rate

71% trial completion

Published Results

11 trials with published results (32%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 64/100

Termination Rate

20.6%

7 terminated out of 34 trials

Success Rate

70.8%

-15.7% vs benchmark

Late-Stage Pipeline

18%

6 trials in Phase 3/4

Results Transparency

65%

11 of 17 completed with results

Key Signals

11 with results71% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (8)
P 1 (3)
P 2 (10)
P 3 (5)
P 4 (1)

Trial Status

Completed17
Terminated7
Unknown5
Recruiting2
Suspended1
Withdrawn1

Trial Success Rate

70.8%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (34)

Showing 20 of 20 trials
NCT07163286Active Not Recruiting

Malnutrition and Sarcopenia Screening in Chemotherapy Patients

NCT06387901Recruiting

Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.

NCT06077123Not ApplicableRecruiting

Telemonitoring Platforms and Chemotherapy-Associated Toxicity

NCT00577798Completed

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

NCT04694794Not ApplicableCompleted

Diminish Chemotherapy Related Side Effects Through Patient Education

NCT01399372Phase 2CompletedPrimary

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT01099449Phase 3CompletedPrimary

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

NCT04572282Not ApplicableUnknown

Mobile App for Symptoms Monitoring in Cancer Patients: a Pilot Study

NCT00748215Phase 2CompletedPrimary

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

NCT04632797Not ApplicableUnknown

Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy

NCT00751101Phase 2Terminated

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

NCT01783522Phase 2TerminatedPrimary

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

NCT01243541Not ApplicableTerminatedPrimary

Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

NCT00755313Completed

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

NCT00754767Phase 4Terminated

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

NCT00775645Phase 3Completed

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo

NCT00728429Not ApplicableTerminated

Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

NCT00499798Completed

Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors

NCT00952848Phase 2CompletedPrimary

Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy

NCT02311907Phase 3CompletedPrimary

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Scroll to load more

Research Network

Activity Timeline